RGNX

6.31

0.24% 0.04

Handel nachbörslich: 6.29 -0.02 -0.32%

Regenxbio Inc (RGNX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$6.35

Offen:

$6.31

24-Stunden-Volumen:

1.27M

Relative Volume:

1.12

Marktkapitalisierung:

$325.95M

Einnahmen:

$170.44M

Nettoeinkommen (Verlust:

$-193.88M

KGV:

-1.6808

EPS:

-3.7541

Netto-Cashflow:

$-126.38M

1W Leistung:

+12.46%

1M Leistung:

-27.34%

6M Leistung:

-52.00%

1J Leistung:

-34.45%

1-Tages-Spanne:

$6.08

$6.385

1-Wochen-Bereich:

$5.57

$6.88

52-Wochen-Spanne:

$5.455

$16.19

Regenxbio Inc Stock (RGNX) Company Profile

Firmenname

Regenxbio Inc

Sektor

Healthcare (1113)

Branche

Biotechnology (618)

Telefon

240-552-8181

Adresse

9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD

Mitarbeiter

371

Twitter

@REGENXBIO

Nächster Verdiensttermin

2026-05-18

Neueste SEC-Einreichungen

RGNX's Discussions on Twitter

Compare RGNX vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RGNX Regenxbio Inc	6.305	328.28M	170.44M	-193.88M	-126.38M	-3.7541
VRTX Vertex Pharmaceuticals Inc	435.92	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.42	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.61	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-28	Fortgesetzt	Barclays	Overweight
2025-02-11	Herabstufung	Goldman	Buy → Neutral
2025-02-07	Fortgesetzt	Raymond James	Outperform
2024-11-15	Fortgesetzt	Morgan Stanley	Overweight
2024-10-10	Fortgesetzt	Raymond James	Outperform
2024-06-07	Eingeleitet	Goldman	Buy
2024-03-11	Eingeleitet	H.C. Wainwright	Buy
2024-03-08	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2024-03-06	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-02-21	Fortgesetzt	Raymond James	Outperform
2023-11-01	Eingeleitet	Stifel	Buy
2023-06-02	Eingeleitet	Robert W. Baird	Outperform
2022-06-23	Eingeleitet	Berenberg	Buy
2021-12-15	Eingeleitet	Wedbush	Neutral
2021-10-19	Fortgesetzt	Morgan Stanley	Overweight
2021-01-06	Hochstufung	Raymond James	Outperform → Strong Buy
2020-12-16	Eingeleitet	UBS	Buy
2020-06-25	Fortgesetzt	BofA/Merrill	Buy
2020-05-13	Eingeleitet	RBC Capital Mkts	Sector Perform
2019-08-20	Hochstufung	SVB Leerink	Underperform → Mkt Perform
2019-06-18	Bestätigt	Chardan Capital Markets	Buy
2019-06-14	Fortgesetzt	Raymond James	Outperform
2019-06-05	Bestätigt	Chardan Capital Markets	Buy
2019-02-25	Hochstufung	Evercore ISI	In-line → Outperform
2019-02-05	Hochstufung	Raymond James	Outperform → Strong Buy
2018-12-17	Bestätigt	Chardan Capital Markets	Buy
2018-11-08	Bestätigt	BofA/Merrill	Neutral
2018-08-08	Bestätigt	Chardan Capital Markets	Buy
2018-07-23	Herabstufung	BofA/Merrill	Buy → Neutral
2018-07-10	Bestätigt	Chardan Capital Markets	Buy
2018-05-09	Bestätigt	Barclays	Overweight
2018-04-09	Bestätigt	Chardan Capital Markets	Buy
2018-03-12	Herabstufung	Evercore ISI	Outperform → In-line
2018-02-13	Eingeleitet	Mizuho	Neutral
2017-11-09	Fortgesetzt	Morgan Stanley	Overweight

Alle ansehen

Regenxbio Inc Aktie (RGNX) Neueste Nachrichten

07:42 AM

Avoiding Lag: Real-Time Signals in (RGNX) Movement - Stock Traders Daily

07:42 AM

12:08 PM

REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies - BioSpace

12:08 PM

May 25, 2026

REGENXBIO to push for accelerated approval of DMD gene therapy - MSN

May 25, 2026

RGNX stock on track for worst day ever as big Q1 loss, cash concerns eclipse Duchenne trial success - MSN

May 25, 2026

May 24, 2026

Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $42 - Moomoo

May 24, 2026

May 20, 2026

RGNX: Rolling BLA for Duchenne gene therapy set for Q3 2024, with robust data and regulatory momentum - TradingView

May 20, 2026

Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway - Insider Monkey

May 20, 2026

Biotech REGENXBIO lines up May investor talks in New York and online - Stock Titan

May 18, 2026

Gene therapy innovation gains momentum at REGENXBIO during ASGCTherapy event - Traders Union

May 18, 2026

Regenxbio slides after late-stage trial data for Duchenne therapy - MSN

May 18, 2026

May 17, 2026

StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate - Genetic Engineering and Biotechnology News

May 17, 2026

What's Behind Regenxbio's Recent Plunge - Kavout

May 17, 2026

REGENXBIO Inc stock (US75901B1052): gene therapy pipeline in focus after recent data update - AD HOC NEWS

May 17, 2026

May 16, 2026

REGENXBIO: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD Results (NASDAQ:RGNX) - Seeking Alpha

May 16, 2026

RegenXBio (RGNX) Gets a Buy from RBC Capital - The Globe and Mail

May 16, 2026

RGNX Technical Analysis & Stock Price Forecast - Intellectia AI

May 16, 2026

May 15, 2026

RGNX Maintained by B of A Securities -- Price Target Lowered to $14 - GuruFocus

May 15, 2026

Bank of America Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - MarketBeat

May 15, 2026

Sarepta's Elevidys Faces 'Little' Pressure After Regenxbio Data, Wedbush Says - Moomoo

May 15, 2026

REGENXBIO Is Maintained at Overweight by Barclays - Moomoo

May 15, 2026

RGNX Maintained by Barclays -- Price Target Lowered to $12 - GuruFocus

May 15, 2026

A Quick Look at Today's Ratings for Regenxbio(RGNX.US), With a Forecast Between $12 to $42 - Moomoo

May 15, 2026

Goldman Sachs Maintains Regenxbio(RGNX.US) With Hold Rating, Cuts Target Price to $10 - Moomoo

May 15, 2026

Nasdaq Jumps Over 200 Points; Dillard's Shares Gain After Q1 Earnings - Sahm

May 15, 2026

Discipline and Rules-Based Execution in RGNX Response - Stock Traders Daily

May 15, 2026

Barclays Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $12 - Moomoo

May 15, 2026

REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval - Sahm

May 15, 2026

Goldman Sachs lowers Regenxbio stock price target on regulatory uncertainty - Investing.com

May 15, 2026

Goldman Sachs lowers Regenxbio stock price target on regulatory uncertainty By Investing.com - Investing.com Canada

May 15, 2026

Regenxbio posts mixed Phase III data on RGX-202 - The Pharma Letter

May 15, 2026